Ask AI
ProCE Banner Activity

CE / CME

Treatment of Bipolar Depression and Mixed Presentations

Video

Mood disorders such as bipolar disorder and depression are often misdiagnosed.  In this activity, an expert describes the continuum of mood disorders from depression to mania, reviews the evidence supporting medications for the treatment of unipolar and bipolar depression, and discusses how to tailor treatment plans based on individual patient and disease state characteristics.

Nurse Practitioners/Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Released: January 20, 2023

Expiration: January 19, 2024

No longer available for credit.

Share

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner

Supporters

This activity is supported by educational grants from Intra-Cellular Therapies, Inc. and AbbVie.

AbbVie

Intra-Cellular Therapies, Inc.

Target Audience

NPs and PAs

Learning Objectives

After completing this activity, participants should be better able to:

  • Describe the dimensional continuum of mood disorder presentations from unipolar to bipolar disorder

  • Identify evidence supporting the use and limitations of mood-stabilizing drugs and second-generation antipsychotics for the treatment of unipolar and bipolar depression

  • Identify the limitations of monoaminergic antidepressants in bipolar depression and major depression with mixed features 

  • Construct evidence-based patient treatment plans based upon patient and disease state-specific characteristics

Disclosure

Partners for Advancing Clinical Education (PACE) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships. 

Charles DeBattista, MD: researcher: Biolite, Compass, Janssen, Myriad, Neurocentia, Relamada, Sage; consultant: AbbVie, Corcept.

Amber Hoberg, PMHNP: consultant: Acadia, Avanir, BioXcel, Intracellular Therapies, Neurocrine, Teva.

Roger McIntyre, MD, FRCPC: consultant: Alkermes, Abbvie, Atai Life Sciences, Axsome, Bausch Health, Eisai, Intracellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, NewBridge Pharmaceuticals, Neumora Therapeutics, Neurocrine, Novo Nordisk, Otsuka, Pfizer, Purdue, Sanofi, Sunovion, Takeda.

Amanda Zimmerman, PA-C: consultant/advisor/speaker: Averitas; researcher: Collegium.

Instructions for Credit

Learners wishing to earn CE/CME credit must: 

  1. View the content in its entirety
  2. Relate the content material to the learning objectives 
  3. Complete evaluation form 

The estimated time to complete this activity is 1.00 hour.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint Accreditation

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

 

Nursing Continuing Professional Development 
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour, including 1.0 hour of pharmacotherapy credit.   

 

AAPA Credit Designation
Joint AccreditationPACE has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until January 19, 2024. PAs should only claim credit commensurate with the extent of their participation.

 


IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.